EXAS

EXAS is currently trading as a high-probability merger arbitrage play following the agreed acquisition by Abbott Laboratories for $105.00 per share in cash. The 'Ground Truth' behind the 3.0% annualized volatility and steady price action ($103.24) is the market pegging the stock to the deal price, with the remaining ~1.7% spread reflecting the time-value of money and residual regulatory closing risk. In the current 'CAUTION (RATES)' regime, this defined-return setup acts as a 'Quality' yield substitute, attractive against a 4.05% 10-year Treasury yield.